Alzheimer's disease affects over 5 million Americans. It's the sixth-highest cause of death in the U.S. There's such an intense demand for effective treatments thatresearch and consulting firm GlobalData projects the market for Alzheimer's disease drugs could top $13 billion by 2023.
Continue Reading Below
Five companies appear to be poised to potentially dominate this market: AstraZeneca (NYSE: AZN), Biogen (NASDAQ: BIIB), Lilly (NYSE: LLY), Merck (NYSE: MRK), and Roche (NASDAQOTH: RHHBY). Here's how they plan to win.
Image source: Getty Images.
The BACE race
One of the approaches being researched to combat Alzheimer's disease focuses onbeta secretase cleaving enzyme (BACE) inhibitors.BACE is an enzyme associated with the development of amyloid beta, which are pieces of protein that clump together and gradually build up into amyloid plaque in the brain. The thought is that inhibiting BACE could prevent the buildup of this plaque and slow progression of Alzheimer's disease.
Three companies stand out as leaders in the race to develop BACE inhibitors for treating Alzheimer's. AstraZeneca and Lilly are working together on AZD3293, which is currently in two late-stage clinical studies. Merck also has a couple of late-stage studies in progress for its experimental Alzheimer's disease drugverubecestat.
AstraZeneca and Lilly recently won Fast Track designation from the U.S. Food and Drug Administration for AZD3293. This means that the FDA will work more closely with the drugmakers in the approval process and could pave the way for a quicker approval.
Merck expects results from the first late-stage study ofverubecestat to be available in late 2017. The company recently announced positive findings from an early-stage study of the drug, with patients at the highest dosage ofverubecestat experiencing an 84% reduction in amyloid beta.
The other primary approach for treating Alzheimer's disease being researched involves use of monoclonal antibodies. Like BACE inhibitors, monoclonal antibodies can potentially prevent the buildup of amyloid plaque.
Lilly is a major player in this alternative Alzheimer's approach, also. The company'ssolanezumab is in a late-stage clinical study. Mid-stage studies of the drug didn't show significant improvement versus placebo. However, Lilly moved forward withsolanezumab anyway, changing the late-stage study in March to only have one primary endpoint: improvement in cognition.
Biogen has its own late-stage monoclonal antibody, aducanumab. The biotech won Fast Track designation foraducanumab in September.Earlier studies showed significant potential for the drug. There's still a long way to go, though. The primary outcome results for the late-stage studies ofaducanumab won't be available until 2020.
Biogen and Lilly aren't the only companies in the hunt for a monoclonal antibody that could potentially be a game changer for Alzheimer's. Roche has two monoclonal antibodies targeting the disease -- gantenerumab and crenezumab. Both are in late-stage clinical studies. Neither drug, however, met primary endpoints in mid-stage studies.Gantenerumab also flopped in a previous late-stage study targeting Alzheimer's disease.
While there's a lot of potential, developing Alzheimer's disease treatments has proven to be a very risky business. Several of the experimental drugs in development have not proven to be effective in earlier studies. Historically, Alzheimer's has one of the worst drug failure rates of any disease. Between 2002 and 2012, only one out of 244 Alzheimer's drug candidates won approval -- a dismal 99.6% failure rate.
It's entirely possible that none of the five companies mentioned succeed. Even Lilly's straddling the fence with a BACE inhibitor candidate and a monoclonal antibody candidate doesn't necessarily give the drugmaker an upper hand.
Still, though, each of these companies has a shot at claiming a stake in what could become a big market. Based on the data available so far, I suspect that Biogen and the AstraZeneca/Lilly partnership have the best chances for success. It's too soon to know for sure, however. Alzheimer's disease is just that tough of an opponent.
Forget the 2016 Election: 10 stocks we like better than Biogen Donald Trump was just elected president, and volatility is up. But here's why you should ignore the election:
Investing geniuses Tom and David Gardner have spent a long time beating the market no matter who's in the White House. In fact, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Biogen wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 7, 2016
Keith Speights has no position in any stocks mentioned. The Motley Fool owns shares of and recommends Biogen. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.